P2RY1 and infection: The documented nonspecific binding of these compounds to multiple diverse targets, paired with the observation that fusion inhibition is only seen with P2RX1 antagonists, renders it unlikely that the inhibition of HIV-1 fusion and infection by these compounds is exclusively resultant of purinergic receptor antagonism.